Recognition of specific sequences in DNA by a topoisomerase I inhibitor derived from the antitumor drug rebeccamycin

Molecular Pharmacology

Volumn 53, Issue 1, 1998, Pages 77-87

  Bailly, Christian ^a   Colson, Pierre ^b   Houssier, Claude ^b   Rodrigues Pereira, Elisabete ^c   Prudhomme, Michelle ^c   Waring, Michael J ^d  

^a INSERM   (France)

^b UNIVERSITY OF LIÈGE   (Belgium)

^c UNIVERSITÉ CLERMONT AUVERGNE   (France)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CIRCULAR DNA; CURVED DNA; DEOXYRIBONUCLEASE I; DNA; DNA TOPOISOMERASE INHIBITOR; REBECCAMYCIN; REBECCAMYCIN DERIVATIVE R 3; REBECCAMYCIN DERIVATIVE R 4; UNCLASSIFIED DRUG;

ARTICLE; DNA FOOTPRINTING; DRUG DNA INTERACTION; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

EID: 0031938920     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.53.1.77     Document Type: Article

References (38)

1. Arakawa H, Iguchi T, Morita M, Yoshinari T, Kojiri K, Suda H, Okura A, and Nishimura S (1995) Novel indolocarbazole compound 6-N-formylamino-12,13-dihydro-1,11-dihydroxy-13-(β-D-glucopyranosyl)-5H- indolo[2,3-a]pyrrolo-[3,4-c]carbazole-5,7-(6H)-dione (NB-506): its potent antitumor activities in mice. Cancer Res 55:1316-1320.
2. Bailly C and Waring MJ (1995a) Transferring the purine 2-amino group from guanines to adenines in DNA changes the sequence-specific binding of antibiotics. Nucleic Acids Res 23:885-892 (1995).
3. Bailly C and Waring MJ (1995b) Comparison of different footprinting methodologies for detecting binding sites for a small ligand on DNA. J Biomol Struct Dyn 12:869-898.
4. Bailly C and Waring MJ (1995c) The purine 2-amino group as a critical recognition element for specific DNA cleavage by bleomycin and calicheamicin. J Am Chem Soc 117:7311-7316.
5. Bailly C, Ridge G, Graves DE, and Waring MJ (1994) Use of a photoactive derivative of actinomycin D to investigate shuffling between binding sites on DNA. Biochemistry 33:8736-8745.
6. Bailly C, Waring MJ, and Travers AA (1995) Effects of base substitutions on the binding of a DNA-bending protein. J Mol Biol 253:1-7.
7. Bailly C, Braña M, and Waring MJ (1996a) Sequence-selective intercalation of antitumour bisnaphthalimides into DNA: evidence for an approach via the major groove. Eur J Biochem 240:195-208.
8. Bailly C, Minnock A, and Waring MJ (1996b) A simple ligation assay to detect effects of drugs on the curvature flexibility of DNA. FEBS Lett 396:253-256.
9. Bailly C, Payet D, Travers AA, and Waring MJ (1996c) PCR-based development of DNA substrates containing modified bases: an efficient system for investigating the role of the exocyclic groups in chemical and structural recognition by minor groove binding drugs and proteins. Pror Natl Acad Sci USA 93:13623-13628.
10. Bailly C, Riou JF, Colson P, Houssier C, Rodrigues-Pereira E, and Prudhomme M (1997) DNA cleavage by topoisomerase I in the presence of indolocarbazole derivatives of rebeccamycin. Biochemistry 36:3917-3929.
11. Bush JA, Long BH, Catino JJ, Bradner WT, and Tomita K (1987) Production and biological activity of rebeccamycin, a novel antitumor agent. J Antibiotics 40:668-678.
12. Capranico G, Kohn KW, and Pommier Y (1990) Local sequence requirements for DNA cleavage by mammalian topoisomerase II in the presence of doxorubicin. Nucleic Acids Res 18:6611-6619.
13. Chaires JB (1996) Molecular recognition of DNA by daunorubicin, in Advances in DNA Sequence Specific Agents (Hurley LH and Chaires JB, eds), Vol 2, pp 141-167. JAI Press, Greenwich, CT.
14. Chaires JB, Herrera JE, and Waring MJ (1990) Preferential binding of daunomycin to 5′(A/T)CG and 5′(A/T)GC sequences revealed by footprinting titration experiments. Biochemistry 29:6145-6153.
15. Drew HR and Travers AA (1984) DNA structural variations in the E. coli tyr T promoter. Cell 37:491-502.
16. Drew HR, Weeks JR, and Travers AA (1985) Negative supercoiling induces spontaneous unwinding of bacterial promoter. EMBO J 4:1025-1032.
17. Fox KR and Waring MJ (1986) Nucleotide sequence binding preference of nogalamycin investigated by DNase I footprinting. Biochemistry 25:4349-4356.
18. Fujii N, Yamashita Y, Mizukami T, and Nakano H (1997) Correlation between the formation of cleavable complex with topoisomerase I and growth-inhibitory activity for saintopin-type antibiotics. Mol Pharmacol 51:269-276.
19. Fujii N, Yamashita Y, Saitoh Y, and Nakano H (1993) Induction of mammalian topoisomerase I-mediated DNA cleavage and DNA unwinding by bulgarein. J Biol Chem 268:13160-13165.
20. Gatto B, Sanders MM, Yu C, Wu HY, Makhey D, LaVoie EJ, and Liu LF (1996) Identification of topoisomerase I as the cytotoxic target of the protoberberine alkaloid coralyne. Cancer Res 56:2795-2800.
21. Houssier C and O'Konski CT (1981) Electro-optical instrumentation systems with their data acquisition and treatment, in Molecular Electro-Optics (Krause S, ed) pp 309-339, Plenum Publishing Corp, New York.
22. Houssier C (1981) Investigating nucleic acids, nucleoproteins, polynucleotides, and their interactions with small ligands by electro-optical systems, in Molecular Electro-Optics (Krause S, ed) pp 363-398, Plenum Publishing Corp, New York.
23. 2. J Mol Biol 231:753-767.
24. I-DNA complex. J Mol Biol 265:187-201.
25. Leatherbarrow RJ (1990) Using linear and non-linear regression to fit biochemical data. Trends Biol Sci 15:455-458.
26. Leteurtre F, Fujimori A, Tanizawa A, Chabra A, Mazumder A, Kohlhagen G, Nakano H, and Pommier Y (1994) Saintopin, a dual inhibitor of topoisomerases I and II, as a probe for drug-enzyme interactions. J Biol Chem 269:28702-28707.
27. Makhey D, Gatto B, Yu C, Liu A, Liu LF, and LaVoie E (1994) Protoberberine alkaloids and related compounds as dual inhibitors of mammalian topoisomerases I and II. Med Chem Res 5:1-12.
28. McGhee JD and von Hippel PH (1974) Theoretical aspects of DNA-protein interaction: co-operative and non-co-operative binding of large ligands to a one-dimensional homogeneous lattice. J Mol Biol 86:469-489.
29. Nabiev I, Chourpa I, Riou JF, Nguyen CH, Lavelle F, and Manfait M (1994) Molecular interactions of DNA-topoisomerase I and II inhibitor with DNA and topoisomerases and in ternary complexes: binding modes and biological effects for intoplicine derivatives. Biochemistry 33:9013-9023.
30. Pommier Y, Kohn KW, Capranico G, and Jaxel C (1993) Base sequence selectivity of topoisomerase inhibitors suggests a common model for drug action, in Molecular Biology of DNA Topoisomerases and Its Application to Chemotherapy (Andoh T, Ikeda H, Oguro M, eds), pp 215-227, CRC Press, London.
31. Pommier Y and Tanizawa A (1993) Mammalian DNA topoisomerase I and its inhibitors, in Cancer Chemotherapy (Hickman JA, Tritton TR, eds) pp 214-250, Blackwell Scientific Publications, Oxford, UK.
32. Rodrigues-Pereira E, Belin L, Sancelme M, Prudhomme M, Ollier M. Rapp M, Servère D, Riou JF, and Fabbro D (1996) Structure-activity relationships in a series of substituted indolocarbazoles: topoisomerase I and protein kinase C inhibition and antitumoral and antimicrobial properties. J Med Chem 39:4471-4477.
33. Smith CK, Davies GJ, Dodson EJ, and Moore MH (1995) DNA-nogalamycin interactions: the crystal structure of d(TGATCA) complexed with nogalamycin. Biochemistry 34:415-425.
34. Waring MJ and Bailly C (1994) DNA recognition by intercalators and hybrid molecules. J Mol Recognit 7:109-122.
35. Wilson WR, Baguley BC, Wakelin LPG, and Waring MJ (1981) Interaction of the antitumor drug 4′-9-acridinylamino)methanesulphon-m-anisidide and related acridines with nucleic acids. Mol Pharmacol 20:404-414.
36. Yamashita Y, Fujii N, Murakata C, Ashizawa T, Okabe M, and Nakano H (1992) Induction of mammalian DNA topoisomerase I mediated DNA cleavage by antitumor indolocarbazole derivatives. Biochemistry 31:12069-12075.
37. Yoshinari T, Matsumoto M, Arakawa H, Okada H, Noguchi K, Suda H, Okura A, and Nishimura S (1995) Novel antitumor indolocarbazole compound 6-N-formylamino-12,13-dihydro-1,11-dihydroxy-13-(β-D-glucopyranosyl)-5H- indolo[2,3-a]pyrrolo-(3,4-c]carbazole-5,7-(6H)-dione (NB-506): induction of topoisomerase I-mediated DNA cleavage and mechanisms of cell line-selective cytotoxicity. Cancer Res 55:1310-1315.
38. Yoshinari T, Yamada A, Uemura D, Nomura K, Arakawa H, Kojiri K, Yoshida E, Suda H, and Okura A (1993) Induction of topoisomerase I-mediated DNA cleavage by a new indolocarbazole, ED-110. Cancer Res 53:490-494.